Back to Search Start Over

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

Authors :
Federica Papaccio
Raimondo Di Liello
Floriana Morgillo
Giuseppe Viscardi
Francesca Sparano
Fortunato Ciardiello
Carminia Maria Della Corte
Giovanna Esposito
Papaccio, Federica
Della Corte, Carminia Maria
Viscardi, Giuseppe
Di Liello, Raimondo
Esposito, Giovanna
Sparano, Francesca
Ciardiello, Fortunato
Morgillo, Floriana
Source :
International Journal of Molecular Sciences, Vol 19, Iss 11, p 3595 (2018), International Journal of Molecular Sciences
Publication Year :
2018
Publisher :
MDPI AG, 2018.

Abstract

An overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) axis promotes tumorigenesis and tumor progression in various cancer types. Research data recently evidenced that HGF/MET signaling is also involved also in the immune response, mainly modulating dendritic cells functions. In general, the pathway seems to play an immunosuppressive role, thus hypothesizing that it could constitute a mechanism of primary and acquired resistance to cancer immunotherapy. Recently, some approaches are being developed, including drug design and cell therapy to combine MET and programmed cell death receptor-1 (PD-1)/programmed cell death receptor-ligand 1 (PD-L1) inhibition. This approach could represent a new weapon in cancer therapy in the future.

Details

Language :
English
ISSN :
14220067
Volume :
19
Issue :
11
Database :
OpenAIRE
Journal :
International Journal of Molecular Sciences
Accession number :
edsair.doi.dedup.....36fb3ee2db505a70548acaf7354ef684